Which companies overlap with China National Center for Cardiovascular Diseases's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Bayer, B&A Therapeutics, Baim Institute for Clinical Research, Aspirus Heart and Vascular Institute-Research and Education.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/china-national-center-for-cardiovascular-diseases.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

China National Center for Cardiovascular Diseases — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

China National Center for Cardiovascular Diseases pipeline: 8 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

8 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
De-escalated Dual Antiplatelet Therapy	De-escalated Dual Antiplatelet Therapy	marketed	Antiplatelet therapy regimen		Cardiovascular
Standard-dose rivaroxaban	Standard-dose rivaroxaban	marketed
Qishen Yiqi Drop Pills	Qishen Yiqi Drop Pills	marketed
Torsemide Tablets	Torsemide Tablets	marketed	Loop diuretic	Na-K-2Cl cotransporter (NKCC2)	Cardiovascular
low-dose rivaroxaban	low-dose rivaroxaban	marketed	Factor Xa inhibitor	Factor Xa	Cardiovascular
Single antiplatelet therapy	Single antiplatelet therapy	marketed	Antiplatelet agent		Cardiovascular
Oral anticoagulation therapy	Oral anticoagulation therapy	marketed	Oral anticoagulant		Cardiovascular
Aspirin + Clopidogrel + Rivaroxaban	Aspirin + Clopidogrel + Rivaroxaban	marketed	Antiplatelet agent + Anticoagulant combination	Platelet cyclooxygenase, P2Y12 receptor, Factor Xa	Cardiovascular
Intensive BP treatment group	Intensive BP treatment group	phase 3			Cardiovascular

Therapeutic area mix

Cardiovascular · 7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 2 shared drug classes
Bayer · 1 shared drug class
B&A Therapeutics · 1 shared drug class
Baim Institute for Clinical Research · 1 shared drug class
Aspirus Heart and Vascular Institute-Research and Education · 1 shared drug class
Beijing Tiantan Hospital · 1 shared drug class
Bristol-Myers Squibb · 1 shared drug class
Asan Medical Center · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for China National Center for Cardiovascular Diseases:

Cite this brief

Drug Landscape (2026). China National Center for Cardiovascular Diseases — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/china-national-center-for-cardiovascular-diseases. Accessed 2026-05-18.